Verrica Completes Enrollment in Key YCANTH Warts Trial, Data Due 2027
Event summary
- Verrica completed enrollment in COVE-2 Phase 3 trial for YCANTH in common warts, with topline data expected Q1 2027.
- COVE-3 trial enrollment exceeds 50% of target, with data anticipated mid-2027.
- Interim analysis confirms no additional patients needed for COVE-2 trial.
- Verrica and Torii share Phase 3 costs equally, with Torii funding first $40M.
- YCANTH is already approved for molluscum contagiosum in US and Japan.
The big picture
Verrica's progress in expanding YCANTH's label to common warts positions it to address one of dermatology's largest unmet needs. The strategic partnership with Torii reduces financial burden while accelerating global approval efforts. Success could significantly expand Verrica's commercial footprint in both US and Japanese markets.
What we're watching
- Regulatory Pathway
- Whether YCANTH can secure FDA approval for common warts, unlocking a multibillion-dollar market opportunity.
- Commercial Strategy
- How Verrica leverages existing sales infrastructure to promote YCANTH for both molluscum and warts.
- Execution Risk
- The pace at which Verrica and Torii can deliver topline data and navigate cost-sharing agreements.